Daniel Grosslight
Stock Analyst at Citigroup
(1.17)
# 3,692
Out of 5,172 analysts
125
Total ratings
33.33%
Success rate
-14.2%
Average return
Main Sectors:
Stocks Rated by Daniel Grosslight
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HCAT Health Catalyst | Maintains: Neutral | $2.75 → $1.75 | $1.23 | +42.28% | 13 | Mar 13, 2026 | |
| HIMS Hims & Hers Health | Upgrades: Neutral | $13 → $24 | $22.02 | +8.99% | 14 | Mar 10, 2026 | |
| TDOC Teladoc Health | Maintains: Neutral | $9 → $6 | $5.35 | +12.15% | 14 | Mar 3, 2026 | |
| PRVA Privia Health Group | Maintains: Buy | $34 → $32 | $21.24 | +50.66% | 2 | Mar 3, 2026 | |
| GDRX GoodRx Holdings | Maintains: Buy | $4.5 → $3.5 | $2.03 | +72.41% | 9 | Mar 3, 2026 | |
| AGL agilon health | Maintains: Neutral | $0.85 → $0.75 | $0.43 | +75.93% | 7 | Mar 3, 2026 | |
| EVH Evolent Health | Maintains: Buy | $6 → $4 | $2.58 | +55.04% | 7 | Feb 26, 2026 | |
| CTEV Claritev | Maintains: Buy | $63 → $21 | $14.89 | +41.03% | 5 | Feb 25, 2026 | |
| WAY Waystar Holding | Maintains: Buy | $46 → $35 | $24.07 | +45.41% | 4 | Feb 18, 2026 | |
| PHR Phreesia | Maintains: Buy | $29 → $25 | $11.86 | +110.79% | 8 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $4 | $1.96 | +104.08% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $190 → $244 | $207.83 | +17.40% | 11 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $820 → $860 | $885.84 | -2.92% | 8 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $10 | $1.48 | +575.68% | 7 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $8 | $9.59 | -16.58% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.25 | $0.60 | +109.70% | 5 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $7 → $3.5 | $5.14 | -31.91% | 2 | Nov 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $9.91 | +31.18% | 1 | Dec 11, 2019 |
Health Catalyst
Mar 13, 2026
Maintains: Neutral
Price Target: $2.75 → $1.75
Current: $1.23
Upside: +42.28%
Hims & Hers Health
Mar 10, 2026
Upgrades: Neutral
Price Target: $13 → $24
Current: $22.02
Upside: +8.99%
Teladoc Health
Mar 3, 2026
Maintains: Neutral
Price Target: $9 → $6
Current: $5.35
Upside: +12.15%
Privia Health Group
Mar 3, 2026
Maintains: Buy
Price Target: $34 → $32
Current: $21.24
Upside: +50.66%
GoodRx Holdings
Mar 3, 2026
Maintains: Buy
Price Target: $4.5 → $3.5
Current: $2.03
Upside: +72.41%
agilon health
Mar 3, 2026
Maintains: Neutral
Price Target: $0.85 → $0.75
Current: $0.43
Upside: +75.93%
Evolent Health
Feb 26, 2026
Maintains: Buy
Price Target: $6 → $4
Current: $2.58
Upside: +55.04%
Claritev
Feb 25, 2026
Maintains: Buy
Price Target: $63 → $21
Current: $14.89
Upside: +41.03%
Waystar Holding
Feb 18, 2026
Maintains: Buy
Price Target: $46 → $35
Current: $24.07
Upside: +45.41%
Phreesia
Jan 9, 2026
Maintains: Buy
Price Target: $29 → $25
Current: $11.86
Upside: +110.79%
Jan 9, 2026
Maintains: Buy
Price Target: $7 → $4
Current: $1.96
Upside: +104.08%
Jan 9, 2026
Upgrades: Buy
Price Target: $190 → $244
Current: $207.83
Upside: +17.40%
Sep 24, 2025
Maintains: Buy
Price Target: $820 → $860
Current: $885.84
Upside: -2.92%
Aug 9, 2023
Maintains: Neutral
Price Target: $9 → $10
Current: $1.48
Upside: +575.68%
Aug 4, 2023
Downgrades: Sell
Price Target: $7 → $8
Current: $9.59
Upside: -16.58%
Apr 28, 2023
Maintains: Neutral
Price Target: $1.5 → $1.25
Current: $0.60
Upside: +109.70%
Nov 16, 2021
Downgrades: Neutral
Price Target: $7 → $3.5
Current: $5.14
Upside: -31.91%
Dec 11, 2019
Initiates: Outperform
Price Target: $13
Current: $9.91
Upside: +31.18%